Abstract
It has been shown that allogeneic intra-bone marrow-bone marrow transplantation (IBM-BMT) plus thymus transplantation (TT) is effective in treating recipients with malignant tumors. Although TT increases the percentage of T cells in the early term after BMT, the myeloid-derived suppressor cells (MDSCs) are still the dominant population. We used the Gr-1 Ab to deplete the granulocytic MDSCs (G-MDSCs) in tumor-bearing mice that had received BMT+TT. Two weeks after the BMT, the mice injected with Gr-1 Ab showed smaller tumors than those in the control group. In addition, Gr-1 Ab significantly increased the percentages and numbers of CD4+ and CD8+ T cells, and decreased the percentages and numbers of MDSCs and G-MDSCs. No side effects of the Gr-1 Ab on recipient or donor thymus were observed. These findings indicate that Gr-1 Ab administered after BMT+TT may enhance the effectiveness of tumor suppression.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Animals, Newborn
-
Antibodies / administration & dosage
-
Antibodies / immunology*
-
Bone Marrow Transplantation / adverse effects*
-
Cell Count
-
Cell Proliferation
-
Granulocytes / cytology*
-
Male
-
Mice
-
Myeloid Cells / cytology*
-
Myeloid Cells / immunology
-
Neoplasms / immunology
-
Neoplasms / pathology
-
Neoplasms / therapy*
-
Receptors, Cell Surface / immunology*
-
T-Lymphocytes / cytology
-
T-Lymphocytes / immunology
-
Thymus Gland / transplantation*
-
Transplantation, Homologous
Substances
-
Antibodies
-
Receptors, Cell Surface
-
granulocyte receptor 1, mouse
Grants and funding
This work was mainly supported by the Otsuka Pharmaceutical Company, Ltd., and by grants from the Research on Allergic Disease and Immunology Committee from the Health and Labour Sciences Research of the Ministry of Health, Labour and Welfare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.